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Abstracts / Osteoarthritis and Cartilage 21 (2013) S9–S62 S55Figure 1. Fstl3 gene deletion results in the loss of load dependent of bone growth
(a) Sagittal section of rat femur showing the position of cross sections. (a-b) Double
ﬂuorochrome-labeled sections of femurs at the distal diaphyseal end at planes I and II
showing minimal bone Deposition in non-loaded control and loaded Fstl3+/+, Fstl3-/-,
and Fstl3+/- mice. Note the bone deposition (i) at the medial (arrow) endosteal surface
in Fstl3+/+ femur as compared to minimal bone formation at all sides of the Fstl3-/-
femur, and (ii) regain of mechanosensitivity in heterozygous mice.
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SCLEROSTIN REGULATION OF WISP1 AND MMPS IN CHONDROCYTES
IS DEPENDENT ON THE LRP5/6 BINDING DOMAIN BUT NOT
SECRETION FROM THE CELL
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Purpose: Sclerostin (SOST) is a secreted protein that inhibits Wnt
signaling by binding the LRP5/6 cell-surface Wnt co-receptor. SOST has
also been reported to bind intra-cellularly and target BMPs for pro-
teosomal degradation in cells in which it is co-expressed. While
previously considered an osteocyte-speciﬁc protein, it has recently been
demonstrated that chondrocytes in non-calciﬁed articular cartilage
express SOST mRNA. Chondrocyte SOST expression is upregulated in
osteoarthritis and by inﬂammatory cytokines such as intereukin-1
(IL-1). Exogenous soluble SOST protects cartilage from IL-1-mediated
proteoglycan loss and inhibits metalloproteinase expression and
activity in vitro, but it is unclear if SOST expressed by chondrocytes
functions in the same manner. The present study aimed to investigate
the function of chondrocyte SOST, and explore the molecular mecha-
nism whereby it may function in this cell type and have chon-
droprotective effects.
Methods: Expression constructs for full length human SOST (WT), non-
secretable SOST (M1), secretable SOST with inactive LRP5/6 binding
domain (M2), and non-secretable SOST with inactive LRP5/6 binding
domain (M3) were generated using a PCR approach. In M2 and M3 the
LRP5/6 binding domain was replaced by the artemin sequence from the
same cysteine-knot familywhich does not bind LRP5/6. SW1353 human
chondrosarcoma cells were stably transfected with the different
constructs or the empty vector. SOST expression was determined by
Western blotting of cell lysates and ELISA quantitation of culture media.
Cells were cultured  IL-1 for 24 hours and cell viability (trypan blue
exclusion), cell metabolism (MTT assay), MMP1, MMP3 and MMP13
gene expression (qRT-PCR), MMP13 protein secretion (Western blot)
and MMP13 activity (ﬂuorogenic assay) were measured.
Results: Transfected cell lines synthesized SOST, with similar levels of
intracellular protein detected in all cells but secreted protein in the
media only in WT and M2 cells as expected. There was no effect of any
of the SOST expression constructs on cell viability or metabolism
compared with the vector control. M1 and M2 constructs decreased
basal (un-stimulated) MMP13 expression. IL-1 stimulated Wnt-b-cat-
enin activity as measured by signiﬁcantly increased WISP1 expression
(p < 0.05). WT and M1 SOST, signiﬁcantly (p<0.05) suppressed IL-1
induced WISP1, MMP1, MMP3 and MMP13 mRNA expression.However only WT SOST decreased MMP13 protein secretion and
activity. In contrast, M2 and M3 constructs had no effect on WISP1 or
MMP gene expression, nor MMP13 activity in the presence or absence
of IL-1.
Conclusion: Our data demonstrate for the ﬁrst time that chondrocytes
can secrete soluble SOST. Furthermorewe show that the LRP5/6 binding
domain is critical for SOSTs inhibition of IL-1 induced Wnt-b-catenin
activation and MMP expression and activity in chondrocytes. Surpris-
ingly however, secretion from the cell was not necessary for SOST to
inhibit IL-1-stimulated WISP1 expression, or for SOSTs anti-MMP
activity. This suggests a hitherto unrecognized intra-cellular role for the
LRP5/6 binding domain of SOST, potentially through cross-talk between
BMP and Wnt pathways. Improved understanding of the regulation of
these molecular pathways in chondrocytes, may lead to novel thera-
peutic approaches in diseases such as osteoarthritis.89
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Purpose: Sclerostin (SCL) is a natural inhibitor of Wnt signaling with
emerging compelling links with the subchondral bone (SB) changes
observed in osteoarthritis (OA). Moreover, it has recently been estab-
lished that SCL regulates bone and cartilage mineralization through the
recognised mineralization inhibitor matrix extracellular phosphogly-
coprotein (MEPE). To establish the expression and function of both SCL
and MEPE in OA, we determined the spatial relationship between their
expression and hallmarks of OA in a spontaneous model of OA, the Str/
ort mouse. Furthermore, as the re-initiation of developmental processes
in OA is well established, we sought to examine the role of SCL in
endochondral ossiﬁcation.
Methods: Knee joints from male Str/ort mice, were analysed at 8, 18
and 40+ weeks of age (before, early and late OA). Age-matched ‘OA
protected’ CBA male mice knees were also analysed. SB-thickness and
epiphyseal mass/architecture parameters were measured by microCT
analysis. Multiple sections from regular intervals across joints were
stained with Toluidine blue and scored for OA hallmarks. SCL and
MEPE expressions were then determined by immunohistochemistry
(IHC). We have previously established the role of MEPE in endochon-
dral bone growth however the role of SCL has yet to be examined. Here
embryonic and postnatal growth plates were analysed by IHC for SCL
expression to establish its temporal and spatial expression in endo-
chondral bone growth. The chondrogenic cell line ATDC5, a model of
endochondral ossiﬁcation, was cultured in mineralizing conditions for
up to 34-days and protein lysates examined for SCL expression by
western blotting.
Results: Our results revealed that SCL expression is enhanced at the
osteochondral interface at unaffected regions of the joint. Similarly,
MEPE expression is enhanced in the articular cartilage (AC) of the
lateral aspect of the Str/ort mouse joint, where SB thickening is not
observed. In OA joints, marked suppression of SCL expression at the
osteochondral interface in Str/ort mice at advanced stages of OA; in
regions of the OA joint where AC integrity is compromised and SB
thickening is observed, as shown by microCT scanning. MEPE expres-
sion is lost in the diseased aspect of the joint in both the AC and the
underlying osteocytes of the SB. Moreover, strong SCL and MEPE
expression is found close to ossiﬁed ligament insertions, menisci, and
in emerging osteophytes, which are increased with disease severity.
Osteophytes form through endochondral ossiﬁcation and as such, we
established the localisation of SCL in endochondral bone growth.
Interestingly, whilst we observe an embryonic expression of MEPE by
both proliferating, and more relevantly mineralizing hypertrophic
chondrocytes, this is lost in postnatal chondrocytes. Our results also
show increased SCL expression in ATDC5 cells throughout the 34-day
differentiation period, suggesting a role for SCL in the endochondral
processes observed in osteophyte formation.
Conclusions: Our data suggest that SCL and MEPE are pivotal in
restricting pathological ossiﬁcation in OA. Further investigation into the
precise mechanisms by which they function in OAwill identify whether
their targeted delivery can protect against OA bone pathology and will
therefore provide a basis for research towards clinical beneﬁt.
